|
|
Outcome
and Vesting
Level
|
||
|
Portion
of
the
Award
|
Measure
and Outcome
|
%
of
maximum
|
%
of
award
|
|
1/3rd
|
Adjusted Free Cash Flow - For the three-year period,
the Company achieved Adjusted Free Cash Flow calculated in
accordance with the principles for the measure of £13bn, which
is above the level of £12.95bn required for maximum
vesting.
Adjustments
to the original target and vesting schedule were communicated in
the 2018 Annual Report.
|
100
|
33.333
|
|
1/3rd
|
Total Shareholder Return - For the three years ending
31 December 2019, the Company's Total Shareholder Return ranked
8th, which is below the threshold vesting level against a
comparator group of 10 global pharmaceutical companies including
GSK.
|
0
|
0
|
|
1/3rd
|
R&D New Products - For the three-year period, the
Company achieved New Product sales calculated in accordance with
the principles for the measure of £7.254bn, which is above the
level of £5.099bn required for maximum vesting. The
threshold level was £4.172bn.
|
100
|
33.333
|
|
|
Total vesting for 2017 award
Lapsed
|
66.666%
33.334%
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr B McNamara
|
|||
|
b)
|
Position/status
|
CEO,
GSK Consumer Healthcare
|
|||
|
c)
|
Initial
notification/Amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The number of ADSs released on an award granted in 2017 under the
Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus
(Co-investment shares) and Matching Award (post-tax).
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$0.00
|
2,391.955 (Co-investment shares)
|
|
||
|
|
$0.00
|
1,614 (Matching Award)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
4,005.955
$0.00
|
||||
|
e)
|
Date
of the transaction
|
2020-03-16
|
|||
|
f)
|
Place
of the transaction
|
N/A
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Mr B McNamara
|
|||
|
b)
|
Position/status
|
CEO,
GSK Consumer Healthcare
|
|||
|
c)
|
Initial
notification/Amendment
|
Initial notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
|
b)
|
Nature
of the transaction
|
The sale of ADSs to meet tax liabilities on the vesting of the
Matching Award under the Company's 2009 Deferred Annual Bonus
Plan.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$33.42
|
825
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date
of the transaction
|
2020-03-16
|
|||
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|||
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
18, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|